Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial

Gideon Koren, Shannon Clark, Gary D V Hankins, Steve N Caritis, Jason G Umans, Menachem Miodovnik, Donald R Mattison, Ilan Matok, Gideon Koren, Shannon Clark, Gary D V Hankins, Steve N Caritis, Jason G Umans, Menachem Miodovnik, Donald R Mattison, Ilan Matok

Abstract

Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo.

Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing.

Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement.

Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy.

Trial registration: Clinical Trial Registration No: NCT00614445 .

References

    1. Koren G, Bishai R. Nausea and Vomiting of Pregnancy: State of the art, 2000. Toronto: The Motherisk Program; 2000. pp. 5–9.
    1. Arsenault MY, Lane CA, MacKinnon CJ, Bartellas E, Cargill YM, Klein MC, et al. SOGC clinical practice guidelines: the management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can. 2002;24(10):817–31.
    1. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128–37. doi: 10.1056/NEJM199804163381607.
    1. Food and Drug administration U.S . Department of Health and Human Services, Public Health Services, Talk Paper. 1983.
    1. Federal Register /Vol. 64, No 152/August 9, 1999/Notes, Determination that Bendectin was not withdrawn from sale for reasons of safety or effectiveness.
    1. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;86(1):66–70.
    1. Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and birth defects. II: ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003;67(2):79–87. doi: 10.1002/bdra.10034.
    1. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A metaanalysis of the epidemiologic studies. Teratology. 1994;50(1):27–37. doi: 10.1002/tera.1420500105.
    1. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988;22(10):813–24.
    1. Diclectin® . Product Monograph. Blainville Quebec, Canada: Duchesnay Inc; 2008.
    1. Nulman I, Koren G. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclectin®) and oral solutions of these drugs in healthy women of childbearing age. Can J Clin Pharmacol. 2009;16(3):e400–6.
    1. Koren G, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol. 2010;203(6):571. doi: 10.1016/j.ajog.2010.07.030.
    1. Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186(5):S228–31. doi: 10.1067/mob.2002.123054.
    1. Koren G, Piwko C, Ahn E, Boskovic R, Maltepe C, Einarson A, et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol. 2005;25(3):241–4. doi: 10.1080/01443610500060651.
    1. Ebrahimi N, Maltepe C, Garcia-Bournissen F, Koren G. Nausea and vomiting of pregnancy: using the 24-hour pregnancy-unique quantification of emesis (PUQE-24) scale. J Obstet Gynecol Can. 2009;31:803–7.
    1. The American College of Obstetricians and Gynecologists Nausea and vomiting of pregnancy. ACOG Practice Bulletin No 52. 2004;103(4):803–15.
    1. Ornstein M, Einarson A, Koren G. Bendectin/diclectin for morning sickness: a Canadian follow-up of an American tragedy. Reprod Toxicol. 1995;9(1):1–6. doi: 10.1016/0890-6238(94)00050-7.
    1. Boskovic R, Einarson A, Maltepe C, Wolpin J, Koren G. Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. J Obstet Gynaecol Can. 2003;25(10):830–3.
    1. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard dose of doxylamine succinate-pyridoxine hydrochloride (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol. 2001;41(8):842–5. doi: 10.1177/00912700122010735.
    1. Nulman I, Rovet J, Barrera M, Knittel-Keren D, Feldman BM, Koren G. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin. J Pediatr. 2009;155(1):45–50. doi: 10.1016/j.jpeds.2009.02.005.
    1. Redelmeie DAR, May SC, Thiruchelvam D, Barrett JF. Pregnancy and the risk of a traffic crash. CMAJ May 12, 2014 doi:10.1503/cmaj.131650.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다